MetaMol Theranostics

MetaMol Theranostics develops a breakthrough diagnostic test for breast cancer risk assessment. The company has identified and validated hOPN-c (osteopontin-C), a protein biomarker that indicates elevated breast cancer risk when detected in breast biopsy samples. Pathologists can apply this test to biopsy specimens to quantify cancer risk, enabling women with breast lumps to make informed treatment decisions. The test delivers risk stratification at a critical clinical decision point, addressing the significant financial and emotional burden of unnecessary breast cancer interventions. MetaMol's diagnostic platform targets pathology laboratories and oncology centers, providing clinical evidence to guide patient management and treatment planning.